In Brief: Genentech
Genentech: Dick Munro to chairman of board. Munro is an eight-year veteran of Genentech's board. Robert Swanson will retire as chairman of the board and from the board of Genentech at the end of 1996. Swanson will still be an advisor and consultant with Genentech and plans to continue work as a venture capitalist identifying and funding "novel young companies working in uncharted areas," the company says...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth